• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Gilead Sciences

How the clinical trial industry is making the most of COVID-19 disruption

December 30, 2020 By Brian Buntz

Like most things in healthcare, clinical trials have been slow to evolve in recent decades. But the COVID-19 pandemic has forced clinical trial research teams to become more efficient, patient-centered and inclusive.   Much is at stake as the pandemic has already caused significant clinical trial disruption. EY estimates that the COVID-19 impact on Phase 3 […]

Filed Under: Clinical Trials, Digital Health, Featured, Pharmaceutical Tagged With: Clinical Trials, coronavirus, COVID-19, external comparators, Gilead Sciences, IQVIA, real-world evidence, RWE, synthetic data

FDA approves remdesivir as a COVID-19 treatment

October 23, 2020 By Sean Whooley

The FDA announced that it fully approved the use of remdesivir as a treatment for COVID-19 requiring hospitalization in all adult and some pediatric patients. Remdesivir is only to be administered in a hospital or healthcare setting capable of providing acute care comparable to inpatient hospital care. The drug, also referred to by the FDA […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: coronavirus, COVID-19, FDA, Gilead Sciences

MedTech 100 roundup: Another high as stocks tick up

August 10, 2020 By Sean Whooley

For the third consecutive week, stocks in the medtech industry reached heights not yet seen since the COVID-19 pandemic began. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.65 points at the end of last week (Aug. 7). Overall, medtech stocks saw a 0.72% increase from […]

Filed Under: Business/Financial News, Diagnostics, Featured, Funding Roundup, Genomics/Molecular Diagnostics, Initial Public Offering (IPO), MassDevice Earnings Roundup, Mergers & Acquisitions, Pharmaceutical, Research & Development, Wall Street Beat Tagged With: 3m, Abiomed, Acutus Medical, becton dickinson, Cardinal Health, CHF Solutions Inc., coronavirus, COVID-19, DeviceTalks Weekly, Dow Jones, Gilead Sciences, Insulet, Johnson and Johnson, Livongo, MedTech 100 Index, Orthofix, Pfizer, ResMed Inc., S&P, Siemens Healthineers, Teladoc, TransEnterix, Varian Medical Systems

Pfizer to make Gilead’s remdesivir COVID-19 treatment

August 7, 2020 By Sean Whooley

Pfizer (NYSE:PFE) announced today that it entered into a multi-year agreement with Gilead Sciences (NSDQ:GILD) to manufacture and supply its antiviral remdesivir treatment. The investigational antiviral remdesivir will be manufactured by Pfizer under the agreement as the company becomes one of the multiple external manufacturing organizations supporting efforts to scale up the supply of the investigational treatment for […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Gilead Sciences, Pfizer

Insitro raises $143m Series B

May 26, 2020 By Sean Whooley

Machine-learning-driven drug discovery and development company Insitro announced today that it raised $143 million in an oversubscribed Series B financing round. San Francisco-based Insitro said in a news release that it plans to use the funds to build its foundations of technology and automation, enabling data generation at a larger scale, expanding its capabilities for […]

Filed Under: Big Data, Business/Financial News, Featured, Funding Roundup, Health Technology, Pharmaceutical, Research & Development, Software / IT Tagged With: Gilead Sciences, Insitro

Gilead licenses remdesivir production to 5 generic drugmakers

May 13, 2020 By Nancy Crotti

Gilead Sciences’ (NSDQ:GILD) said Tuesday that it has signed licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir, the experimental drug being used in the U.S. to treat COVID-19. The non-exclusive, voluntary agreements allow the companies — Mylan (NSDQ:MYL), Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences — […]

Filed Under: Business/Financial News, Distribution, Featured, Pharmaceutical Tagged With: Cipla, COVID-19, Drug Controller General of India, FDA, Ferozsons Laboratories, Gilead Sciences, Hetero Labs, Indian Council of Medical Research, Jubilant Lifesciences, Mylan

BREAKING: FDA grants emergency use of drug to treat COVID-19

May 1, 2020 By Nancy Crotti

The FDA this afternoon issued an emergency use authorization for the investigational antiviral drug remdesivir to treat severely ill COVID-19 patients. The authorization for the drug, made by Gilead Sciences’ (NSDQ:GILD), will allow both adults and children to  be treated with the remdesivir, the first drug believed to have any effect on the virus that has […]

Filed Under: Business/Financial News, Clinical Trials, Distribution, Featured, Food & Drug Administration (FDA), Hospital Care, Pharmaceutical, Regulatory/Compliance, Research & Development Tagged With: coronavirus, COVID-19, FDA, Gilead Sciences, National Institutes of Health (NIH)

Fauci: Hundreds of millions of COVID-19 vaccine doses could be ready in January

April 30, 2020 By Nancy Crotti

Dr. Anthony Fauci said this morning that hundreds of millions of doses of a vaccine for COVID-19 could be ready by January. In an interview on the Today Show, the director of the National Institute of Allergy and Infectious Diseases said that a vaccine candidate is in the first phase of a clinical trial. If […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Hospital Care, Pharmaceutical, Research & Development Tagged With: coronavirus, COVID-19, Gilead Sciences, National Institutes of Health (NIH)

Here are the pharma companies accused of blocking generic competition

May 17, 2018 By Sarah Faulkner

To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]

Filed Under: Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Actelion, Celgene, FDA, Gilead Sciences, GlaxoSmithKline plc, Johnson and Johnson, Novartis, Valeant Pharmaceuticals

Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease

May 1, 2018 By Sarah Faulkner

Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases. By probing immune cells from patients involved in Gilead’s clinical trials, the companies hope to glean a better understanding of the immunological signatures of RA, IBD and […]

Filed Under: Clinical Trials, Diagnostics, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Gilead Sciences, Verily

This company helps cell therapies travel around the world

October 19, 2017 By Sarah Faulkner

With Gilead Sciences (NSDQ:GILD) and Novartis (NYSE:NVS) leading the way, cell therapies are moving on to the market and into the clinics for patients that have no other option. Companies making CAR-T therapies use a patient’s own cells to genetically engineer a cancer-killing cellular therapy that is then delivered back to the patient. We are so grateful that we […]

Filed Under: Clinical Trials, Pharmaceutical, Wall Street Beat Tagged With: cryoport, Gilead Sciences, kitepharma, Novartis

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS